Fate therapeutics showcases positive interim phase 1 data from ft596 off-the-shelf, ipsc-derived car nk cell program for relapsed / refractory b-cell lymphoma at 2021 ash annual meeting

5 of 6 patients achieve objective response, including 4 patients with complete response, with single dose of ft596 at 900 million cells in combination with rituximab
FATE Ratings Summary
FATE Quant Ranking